The new infusion of capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.

Founded in 2016, CytoReason already has partnerships with top global pharmaceutical companies.

The company's propriety platform combines scientific and experimental data for immune system simulations applicable to cancer immunotherapy, and autoimmune, neurodegenerative and infectious disease research.